Differences of clinical and laboratory features between dipeptidyl peptidase-4 inhibitor-related and nondipeptidyl peptidase-4 inhibitor-related bullous pemphigoid: A systematic review and meta-analysis - 17/07/25
Doi : 10.1016/j.jaad.2025.02.095
Yi-Hsuan Shen, MD a, Yu-Chen Huang, MD a, b, c, ⁎ 
a Department of Dermatology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan
b Research Center of Big Data and Meta-Analysis, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan
c Department of Dermatology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
∗Correspondence to: Yu-Chen Huang, MD, Department of Dermatology, Wan Fang Hospital, Taipei Medical University, 111, Hsing-Long Road Sec. 3, Wenshan District, Taipei City, 116, Taiwan (R.O.C.)Department of DermatologyWan Fang HospitalTaipei Medical University111Hsing-Long Road Sec. 3Wenshan DistrictTaipei City116Taiwan (R.O.C.)
Key words : autoimmune bullous dermatoses, bullous pemphigoid, DPP-4 inhibitors
| Funding sources: None. |
|
| Patient consent: Not applicable. |
|
| IRB approval status: Not applicable. |
© 2025
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 93 - N° 2
P. 499-501 - août 2025 Retour au numéro
Article précédent
- Recurrence of cutaneous squamous cell carcinoma in situ with follicular involvement
- Nathan Shen, Austen Callister, Scott R. Florell, Abigail Florell, Kenneth M. Boucher, Alice Frigerio, Douglas Grossman
- Efficacy of dupilumab for chronic kidney disease-associated pruritus in patients undergoing hemodialysis: Retrospective observational study
- Zhiwen Wang, Chen Chen, Yu Xiong, Yingying Feng, Junchen Chen, Hui Xu
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?